Amgen Inc. (NASDAQ:AMGN) Stock Position Lifted by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its position in Amgen Inc. (NASDAQ:AMGN) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,427 shares of the medical research company’s stock after acquiring an additional 54 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Amgen were worth $3,682,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in AMGN. Strategic Financial Concepts LLC bought a new position in shares of Amgen in the 2nd quarter worth about $26,000. Hershey Financial Advisers LLC acquired a new position in Amgen in the second quarter valued at approximately $30,000. nVerses Capital LLC bought a new position in shares of Amgen during the second quarter valued at approximately $31,000. Bbjs Financial Advisors LLC bought a new position in shares of Amgen during the second quarter valued at approximately $33,000. Finally, Matrix Trust Co acquired a new stake in shares of Amgen during the 3rd quarter worth approximately $36,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on AMGN shares. Royal Bank of Canada restated an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. Barclays lifted their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Morgan Stanley decreased their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Finally, StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Amgen Stock Down 0.3 %

Amgen stock opened at $319.22 on Monday. The firm’s 50 day moving average price is $324.47 and its two-hundred day moving average price is $315.90. The firm has a market cap of $171.53 billion, a PE ratio of 40.87, a P/E/G ratio of 2.89 and a beta of 0.60. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.89 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same period last year, the company earned $4.96 earnings per share. Amgen’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, research analysts predict that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.